HCA Warning, Leqembi SubQ, FTC CVS, ICER Advice

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning. The HCA warning alone feels like a bellwether moment.

MarcusSame here. We're looking at HCA's profit warning — signals of access erosion in US healthcare systems. Then subcutaneous Leqembi approval — how this reshapes Alzheimer's value narrative. And the FTC-CVS insulin settlement — implications for PBM practices and insulin access. Plus ICER's early-phase scientific advice expansion.

SaraThat second one is particularly interesting — the budget impact question there is one the field hasn't fully worked out yet, especially with comparative effectiveness against existing amyloid-targeting agents.

MarcusExactly. Let's get into it.

MarcusHCA Healthcare's profit warning is stark. They cite rising uncompensated care and charity care costs, driven by increased uninsured patients and higher bad debt. This isn't just a financial hiccup—it suggests systemic access erosion where hospitals absorb costs that previously flowed through commercial payers. The self-pay patient surge signals broader affordability pressures.

SaraWhat strikes me is how this mirrors pre-ACA uninsured trends. But now it's hitting for-profit systems hardest, which traditionally had thinner margins for uncompensated care. The question is whether this forces structural changes in hospital reimbursement models or just shifts costs elsewhere.

MarcusThat connects to something I keep coming back to: the IRA's inflation rebates don't address this segment. Hospitals aren't seeing drug price relief—they're bearing the brunt of coverage gaps. I wonder if that's the full picture though—could this also reflect broader economic pressures beyond just insurance status?

SaraFair point, but HCA specifically called out charity care increases. Historically, these spikes correlate with Medicaid coverage expansions contracting. The part that gives me pause is whether we're entering a new era where safety-net hospitals become the default for underinsured populations, creating two-tiered access.

MarcusThat's one read—I'd frame it slightly differently. This could accelerate value-based contracting between hospitals and payers to mitigate losses. But the data shows uncompensated care is rising faster than inflation, which suggests systemic strain rather than temporary fluctuation. The precedent here is the 2010s hospital closures in rural areas.

SaraRight, and from the payer side, this means higher cross-subsidization costs embedded in commercial premiums. It's a classic cost-shifting scenario. The methodology challenge will be quantifying the opportunity cost of diverted resources from planned investments in infrastructure.

MarcusExactly. The patient impact is undeniable—delays in care for underinsured populations. But the system sustainability question is how long hospitals can absorb these losses before passing them fully to payers or patients. This story caught me off guard in its severity.

SaraMe too. The scale of the profit warning suggests this isn't cyclical. We'll be watching how CMS responds with 2027 hospital payment rules.

SaraFDA's subcutaneous Leqembi approval is significant beyond just convenience. It reduces infusion burden from 2.5 hours to 10 minutes, which could dramatically improve real-world adherence. But the HEOR implications run deeper—this formulation enables broader real-world evidence generation on long-term outcomes in less controlled settings.

MarcusThat's fair, though I think payers would see it differently. The route change doesn't alter the core cost-effectiveness challenge. What's striking here is how this shifts the comparative effectiveness landscape. Now we need head-to-head RWE against other anti-amyloid agents, not just placebo-controlled trials.

SaraI'd push back slightly on that. The administration route directly impacts utility scores—fewer side effects and less time burden could translate to meaningful QALY gains. The methodological observation here is that HTA bodies will need to incorporate route-specific utilities into their models, which has precedent in oncology but not yet in neurodegeneration.

MarcusWhat strikes me is the commercial viability angle. Faster administration could expand eligible patient populations beyond current infusion centers. But the evidence gap is real—we don't have RWE on whether subcutaneous delivery maintains the same efficacy profile in real-world settings. That's a methodological blind spot.

SaraExactly. The part that gives me pause is how this interacts with CMS coverage decisions. If adherence improves, long-term budget impact could improve, but only if we see sustained cognitive benefits. The historical precedent here is how subcutaneous MS therapies changed value assessments through adherence data.

MarcusThat's one read—but I'm more interested in how this affects comparative effectiveness research. Now we need RWE comparing subQ Leqembi to existing oral amyloid inhibitors, not just placebo. This could reshape the Alzheimer's value narrative entirely if it shows non-inferiority with better tolerability.

SaraI wonder if that's the full picture though. The payer lens is that this reduces operational costs for providers, which could offset some drug acquisition expenses. But the evidence requirement remains: we need real-world data on whether the route change translates to meaningful functional improvements beyond cognitive scores.

MarcusAgreed. The patient perspective is clear—less burden is better. But for HEOR, this opens a new frontier in route-specific evidence generation. We'll be watching ICER's next Alzheimer's report for how they incorporate this.

MarcusThe FTC-CVS settlement over insulin pricing is a landmark moment. CVS agreed to pay $75 million and change incentive programs after steering patients to higher-cost insulin products. This isn't just about one company—it exposes systemic PBM practices that inflate costs through formulary design and rebate structures. The precedent here could reshape how PBMs are compensated.

SaraThat connects to something I keep coming back to: the opportunity cost of these practices. When PBMs steer patients to costlier products, it diverts resources from other high-value interventions. The methodology observation is that this settlement forces transparency around PBM rebate structures, which have historically been black boxes in budget impact models.

MarcusI'd frame it slightly differently. This signals regulatory scrutiny shifting from drug manufacturers to PBMs. What's interesting is how this interacts with IRA insulin price caps—if PBMs were steering patients to higher-cost products despite caps, it suggests the caps alone won't solve access issues. The patient impact is clear: higher out-of-pocket costs.

SaraExactly. The part that gives me pause is whether this creates a new evidentiary standard for PBM practices. HTA bodies may now require formulary transparency as part of value assessments. The historical precedent is how CMS's PBM transparency rules in Medicare Advantage changed value-based contracting.

MarcusThat's one read—but I'm more focused on the competitive dynamics. If PBMs can't steer patients to preferred products, how will they differentiate? This could accelerate value-based contracting models where PBMs share savings for cost-effective products. But the evidence challenge is proving steerage occurred beyond just formulary placement.

SaraFair point, but the settlement specifically cited antitrust violations, not just formulary design. The methodological shift here is that HEOR teams must now model PBM incentive structures, not just list prices. This is a fundamental change in how we calculate net prices.

MarcusI wonder if that's the full picture though. The broader implication is that PBMs may reduce rebate sharing with pharmacies, potentially increasing net costs for patients. The patient perspective is critical here—any savings from reduced steerage must be passed through to consumers. This story caught me off guard in its direct challenge to PBM business models.

SaraMe too. We'll be watching how other PBMs adjust their incentive structures post-settlement.

SaraICER's expansion of early-phase scientific advice to Phase I/II is a strategic pivot. Offering guidance before Phase III could de-risk development by aligning evidence generation with HTA requirements. This is particularly valuable for rare diseases where traditional endpoints may not capture meaningful benefit. The methodology shift is moving value assessment earlier in the pipeline.

MarcusThat's one read—I'd frame it slightly differently. This addresses the innovation paradox: how to fund high-risk development when HTA comes too late. What strikes me is how this could reduce late-stage attrition by ensuring endpoints meet payer expectations early. But the evidence challenge is whether early advice truly prevents development failures versus just delaying them.

SaraThe part that gives me pause is the resource implication. ICER's capacity is already strained with full appraisals. Scaling this to early phases could create bottlenecks unless they streamline processes. The historical precedent is how NICE's early advice program changed development timelines for ultra-orphan drugs.

MarcusExactly. And from the industry perspective, this could accelerate RWE generation by identifying data gaps before Phase III. But I wonder if that's the full picture though—early advice might over-constrain innovation by forcing developers into narrow HTA frameworks. The patient angle is promising: faster access for therapies meeting early value signals.

SaraI'd push back slightly on the constraint concern. The alternative is late-stage failures that waste resources. The methodological observation here is that early advice could standardize endpoints across HTA bodies, reducing the need for jurisdiction-specific evidence generation. That's a global efficiency gain.

MarcusThat's fair, but the commercial viability question remains. If early advice sets high evidentiary bars, could it deter investment in high-risk, high-reward areas? The evidence precedent here is how early scientific advice for CAR-T therapies shaped trial designs but also increased development costs.

SaraRight, and from the payer side, this could improve budget predictability by flagging high-cost therapies earlier. But the operational hurdle is whether HTA bodies can provide timely advice without diverting resources from ongoing appraisals. This is one of those stories where the theory is compelling but execution will be key.

MarcusAgreed. The transformative potential is real—aligning development with value earlier. But we'll need to see how ICER manages the scale-up. This could redefine the HEOR evidence generation timeline.

SaraA lot to think about today. I'll be watching how CMS responds to the HCA warning with 2027 hospital payment rules—whether it signals broader access policy shifts.

MarcusSame — and for me the thread running through today is how regulatory actions are forcing structural changes in healthcare financing, from PBMs to hospital reimbursement. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.